Literature DB >> 7454435

Comparison of cytosolic and mitochondrial hepatic enzyme alterations in Reye's syndrome.

R A Mitchell, M L Ram, E L Arcinue, C H Chang.   

Abstract

The activities of nine enzymes in liver specimens obtained from four children who had died from Reye's syndrome were compared to the corresponding activities of a control group of four children who had died from unrelated causes. At the 95% significance level, the alterations could be classified into three groups. Five activities [lactate dehydrogenase, alanine aminotransferase, glucose 6-phosphatase, cytochrome oxidase, and malate dehydrogenase (mitochondrial plus cytosolic)] showed no change. Three enzymes [glutamate dehydrogenase, isocitrate dehydrogenase (NADP), and monoamine oxidase] were decreased. One activity (glucose 6-phosphate dehydrogenase) was increased. The malate dehydrogenase isozymes were resolved by electrophoresis, and the two bands were stained and measured. The ratio of cytosolic:mitochondrial enzyme was significantly greater in Reye's syndrome than in the control group. These results lend further support to the view that in Reye's syndrome the impairment of hepatic function is largely confined to the mitochondria. The lowered activity of monoamine oxidase means that the abnormalities extend to the outer mitochondrial membrane. Imbalances of the cytosolic:mitochondrial enzyme activities were evaluated in needle biopsy specimens from four other children under conditions where neurologic abnormalities were less severe. Two patients had elevated ratios of both glutamate:lactate dehydrogenase and cytosolic:mitochondrial malate dehydrogenase activities, and a third had only an abnormal malate dehydrogenase ratio. In contrast to these Reye's syndrome patients, a fourth case admitted with a provisional diagnosis of Reye's syndrome showed no abnormality in either ratio in stage IV coma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7454435     DOI: 10.1203/00006450-198011000-00013

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  A morphometric study of Reye's syndrome. Correlation of reduced mitochondrial numbers and increased mitochondrial size with clinical manifestations.

Authors:  C C Daugherty; P S Gartside; J E Heubi; K Saalfeld; J Snyder
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

2.  Reye's syndrome.

Authors:  M Lesna; C Boyd
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-29

3.  Complex changes in the liver mitochondrial proteome of short chain acyl-CoA dehydrogenase deficient mice.

Authors:  Wei Wang; Al-Walid Mohsen; Guy Uechi; Emanuel Schreiber; Manimalha Balasubramani; Billy Day; M Michael Barmada; Jerry Vockley
Journal:  Mol Genet Metab       Date:  2014-03-12       Impact factor: 4.797

Review 4.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

5.  Defects of metabolism of fatty acids in the sudden infant death syndrome.

Authors:  A J Howat; M J Bennett; S Variend; L Shaw; P C Engel
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

6.  Deficiency of medium chain fatty acylcoenzyme A dehydrogenase presenting as the sudden infant death syndrome.

Authors:  A J Howat; M J Bennett; S Variend; L Shaw
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-31

7.  Interactions of aspirin and other potential etiologic factors in an animal model of Reye syndrome.

Authors:  D R Deshmukh; H F Maassab; M Mason
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Liver lipid profiles of adults taking therapeutic doses of aspirin.

Authors:  J L Rabinowitz; D G Baker; T G Villanueva; A P Asanza; D M Capuzzi
Journal:  Lipids       Date:  1992-04       Impact factor: 1.880

Review 9.  Reye syndrome.

Authors:  D C De Vivo
Journal:  Neurol Clin       Date:  1985-02       Impact factor: 3.806

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.